Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pilot liquid emulsion for asthma

This article was originally published in The Tan Sheet

Executive Summary

Airozin medical food for dietary maintenance of asthma is slated to launch April 7 at supermarkets, drugstores in the Carolinas, Pilot says. AC Nielsen will test direct and retail marketing to gauge success, firm notes. Airozin launch has been postponed twice, most recently due to flavor reformulation; product now is a mint, rather than citrus-flavored, liquid emulsion. Previously, the Charleston, S.C.-based firm delayed launch plans while awaiting the completion of clinical trials supporting product's efficacy (1"The Tan Sheet" Nov. 4, 2002, p. 16). Two studies, one on Airozin's safety and pharmacokinetics, are slated for publication in the March Clinical Therapeutics. Firm is sponsoring Charleston Asthma Summit April 10 to educate physicians, pharmacists, advocacy groups on asthma management...

You may also be interested in...



Pilot’s Airozin Medical Food For Asthma To Launch By Year End

Pilot Therapeutics plans to introduce its asthma maintenance therapy, Airozin, by the end of 2002 after a six-month delay, the company said

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel